© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Marinus Pharmaceuticals, Inc. (MRNS) shows an Average True Range (ATR) of 0.01 and an Enterprise Value of 68.47M. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into MRNS's underlying financial health and market activity.
Marinus Pharmaceuticals, Inc. (MRNS) technical indicators as of December 22, 2025: the SMA 20 is 1.11%, SMA 50 at 28.39%, and SMA 200 at -48.32%. The RSI 14 value is 70.4, suggesting its current momentum. These technical analysis signals help assess MRNS's price trends and potential future movements.
Marinus Pharmaceuticals, Inc. (MRNS) stock performance overview as of December 22, 2025: The 52-week high is $0.556 (currently -94.76% below), and the 52-week low is $0.22 (currently 149.77% above). Over the past year, MRNS's performance is N/A, compared to the S&P 500's 12.87% change.
According to market data, Marinus Pharmaceuticals, Inc. (MRNS) stock's recent performance metrics show that over the last month, MRNS is 2.42%, with a Year-to-Date (YTD) performance of 2.78%. Over the past year, the stock has seen a N/A change. These figures summarize MRNS's price movements across various periods, reflecting its historical returns.
According to current financial data, MRNS stock's P/E (TTM) ratio is -0.52, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for MRNS, including P/S (1.83), P/B (-0.47), and P/FCF (-0.59), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.